

(FILE 'HOME' ENTERED AT 12:43:52 ON 07 FEB 2002)

FILE 'BIOTECHNO, CONFSCI, BIOTECHDS, JAPIO' ENTERED AT 12:44:21 ON 07

FEB

2002

L1 19 S BAEZA M?/AU
L2 9 S BAEZA I?/AU
L3 100 S AGUILAR J?/AU
L4 57 S AGUILAR L?/AU
L5 268 S RAMIREZ M?/AU
L6 56 S RAMIREZ I?/AU
L7 0 S FAISAL J?/AU
L8 0 S FAISAL L?/AU
L9 793 S WONG C?/AU
L10 86 S RAMIREZ C?/AU
L11 51 S IBANEZ M?/AU
L12 33 S IBANEZ A?/AU
L13 405 S HERNANDEZ M?/AU
L14 331 S HERNANDEZ A?/AU
L15 45 S LARA M?/AU
L16 0 S UC M?/AU
L17 2235 S L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR
L18 49 S L17 AND (LIPID? OR LUPUS?)
L19 58 S L17 AND (LIPOSOM? OR ERYTHROCYT? OR LEUKOCYT? OR PLAQUETT?
OR
L20 52 S L19 NOT L18
L21 101 S L18 OR L19
L22 12 S L21 AND ANTIBOD?

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 12:50:07 ON
07 FEB 2002

L23 36165 S L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR
L24 839 S L23 AND (LIPID? OR LUPUS?)
L25 1043 S L23 AND (LIPOSOM? OR ERYTHROCYT? OR LEUKOCYT? OR PLAQUETT? O
L26 1813 S L24 OR L25
L27 167 S L26 AND ANTIBOD?
L28 86 DUPLICATE REMOVE L27 (81 DUPLICATES REMOVED)
L29 12 S L28 AND (PHOSPHOLIPID? OR ANTIPHOSPHOLIPID? OR ANTI-PHOSPHO?

(FILE 'HOME' ENTERED AT 12:37:16 ON 07 FEB 2002)

FILE 'BIOTECHNO, CONFSCI, BIOTECHDS, JAPIO' ENTERED AT 12:37:25 ON 07.

FEB

2002

L1	0 S BAEZA-RAMIREZ M?/AU
L2	0 S AGUILR-FAISAL J?/AU
L3	0 S WONG-RAMIREZ C?/AU
L4	0 S IBANEZ-HERNANDEZ M?/AU
L5	0 S LARA-UC M?/AU
L6	0 S UC M?/AU
L7	45 S LARA M?/AU
L8	0 S L7 AND LIPID?

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 12:40:43 ON
07 FEB 2002

L9	0 S L1 OR L2 OR L3 OR L4 OR L5
----	--------------------------------

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments
1	BRS	L1	0	baeza-ramirez\$.in.	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2002/02/07 12:41	
2	BRS	L2	0	wong-ramirez\$.in.	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2002/02/07 12:42	
3	BRS	L3	0	aguilr-faisal\$.in.	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2002/02/07 12:42	
4	BRS	L4	0	ibanez-hernandez\$.in.	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2002/02/07 12:42	
5	BRS	L5	0	lara-uc\$.in.	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2002/02/07 12:42	

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments
6	BRS	L6	9	escuela\$.as.	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2002/02/07 12:42	

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments
1	BRS	L2	0	baeza-i\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:54	
2	BRS	L3	56	aguilar-j\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:54	
3	BRS	L5	39	ramirez-m\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:54	
4	BRS	L7	0	faisal-j\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:54	
5	BRS	L9	882	wong-c\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:54	

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments
6	BRS	L10	68	ramirez-c\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:55	
7	BRS	L11	38	ibanez-m\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:55	
8	BRS	L13	144	hernandez-m\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:55	
9	BRS	L14	139	hernandez-a\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:55	
10	BRS	L16	0	uc-m\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:55	

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments
11	BRS	L1	3	baeza-m\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:56	
12	BRS	L4	3	aguilar-l\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:56	
13	BRS	L6	8	ramirez-i\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:56	
14	BRS	L8	1	faisal-l\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:57	
15	BRS	L15	17	lara-m\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:57	

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments
16	BRS	L12	18	ibanez-a\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:59	
17	BRS	L17	1366	3 or 5 or 9 or 10 or 11 or 13 or 14	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:59	
18	BRS	L18	26	17 and (lipid or lupus)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:59	
19	BRS	L19	0	17 and lipidic	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 12:59	
20	BRS	L20	20	17 and (liposome or erythrocyte or leukocyte or plaquette or neoplastic)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 13:00	

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments
21	BRS	L21	2	17 and leucocyte	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 13:00	
22	BRS	L22	43	18 or 20 or 21	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 13:00	
23	BRS	L23	12	22 and antibody	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 13:00	
24	BRS	L24	12	22 and antibodies	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/02/07 13:01	

-PAT-NO: 6261792

DOCUMENT-IDENTIFIER: US 6261792 B1

TITLE: Lipid-dependent diagnostic assays

----- KWIC -----

Detailed Description Text - DETX (7):

The phospholipid is one which has a hexagonal (H.sub.II) organization when dispersed in an aqueous medium without detergent under the conditions of the assay. Such "conditions of the assay" include, but are not limited to, temperature, concentration of all components, ionic concentrations, pH, etc. Many such assays are conducted at 37.degree. C., and therefore for such assays the phospholipid must be in H.sub.II form at that temperature. Examples of phospholipids which are suitable for use in the present invention include dioleoylphosphatidylethanolamine (DOPE), egg phosphatidylethanolamine (EPE), and bovine phosphatidylethanolamine and certain phosphatidic acids. In addition, cardiolipin can be in hexagonal (H.sub.II) phase when provided in combination with calcium ions, as is well known in the art. Of these, DOPE is particularly suitable because it is a synthetic phospholipid and thus generally freer of contaminants than the phospholipids derived from natural sources. As discussed above, it is the purity of DOPE that has also made it particularly hard to maintain in suspension and handle in assay procedures.

US-PAT-NO: 6096335

DOCUMENT-IDENTIFIER: US 6096335 A

TITLE: Stable particulate complexes having a lamellar, rolled, and condensed structure

----- KWIC -----

Detailed Description Text - DETX (74):

Thus, by increasing membrane fluidity, the non-aqueous, hydrophilic, polar solvent facilitates the thermodynamic equilibrium leading to the creation of this particulate structure despite the opposing ionic forces of the various constituents, and provides neutral or negative lipoplexes (Neutraplex.TM. complexes). Some suitable non-aqueous, hydrophilic, polar solvents are mentioned above. The preferred solvent is ethanol. In addition to Cardiolipin, which is prone to form a hexagonal phase, the solvent helps in obtaining the hexagonal liquid crystalline phase in Neutraplex.TM. complexes.

HEXAGONAL

CARDIOLIPIN

↓
103
=

Detailed Description Text - DETX (115):

The cryoEM images of punctate Neutraplexrm particles formed with T4 DNA that we observe are strikingly similar to the images of phase lambda (Lepault et al.) complete tail-deletion mutant of T4 (Lepault et al.) and T7 phages (Cerittelli et al.) These T4-related phage particles showed a spherical shape and an average diameter of 80 nm.^{sup.30}. Recent investigations (Lepault et al., Cerittelli et al.) performed by using tailless mutants, indicated DNA packing

domains in viral particles. It is noteworthy that T7 tail-deletion mutants exhibit in cryoEM images a concentric ring motif as well as a punctate motif as observed for Neutraplex.TM. (Nx)-pDNA. Neutraplex.TM.-T4 and -pDNA cryo-EM images and SAXS illustrate the structural transition of lamellar and hexagonal phases in Neutraplex.TM.. This hexagonal liquid crystalline phase results from the use of a hydrophilic, non-aqueous solvent and compounds such as DOPE or Cardiolipin. Cerritelli et al. indicated that the state of DNA compaction in phage viral particles should correspond to the 3-D hexagonal crystalline phase of DNA. Nx1D-pDNA according to example 2 present as well the lamellar liquid crystalline phase. Cryo-EM observation of Neutraplex.TM.es was made in salt containing media and reproducible up to at least three months.